Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0BDIBY
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
RNAse monoclonal antibody-LL2-I-131-conjugate
|
|||||
| Synonyms |
Monoclonal antibody LL2I131 RNAse conjugate; RNAse conjugate Immunomedics; RNAseLymphoCide conjugate Immunomedics
Click to Show/Hide
|
|||||
| Organization |
Immunomedics, Inc.; Gilead Sciences, Inc.
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 2 Indication(s)
Non Hodgkin lymphoma [ICD11:2B33]
Clinical candidate
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Clinical candidate
|
|||||
| Antibody Name |
Epratuzumab
|
Antibody Info | ||||
| Antigen Name |
B-cell receptor CD22 (CD22)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
Undisclosed
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.